Business
Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO® in Canada from Knight
TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ...
About this update from Profound Medical Corp
[{"type":"text","content":"Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO® in Canada from Knight\n\n\n\n TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) --\n \n\n Profound Medical Corp.\n \n\n (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets artificial intelligence (“AI”)-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that it has regained exclusive distribution rights for TULSA-PRO\n \n ®\n \n in Canada from Knight Therapeutics Inc. (“Knight”).\n \n\n The\n \n TULSA Procedure™\n \n , performed using the TULSA-PRO system, is used by physicians to ablate prostate tissue in men suffering from prostate cancer and/or benign prostatic hyperplasia (“BPH”, also known as an enlarged prostate).\n \n\n Pursuant to an agreement entered into with Knight in April 2015, Knight had acted as Profound’s exclusive distributor for the technology in Canada. Profound has now regained the Canadian TULSA-PRO distribution rights from Knight in return for a one-time cash payment of CDN$90,000 (US$64,000) and a 5% royalty on Canadian Net Sales for 15 years.\n \n\n “Knight has been a strong supporter of Profound and its groundbreaking TULSA technology for the treatment of prostate disease, including cancer and/or BPH,” said Samira Sakhia, President and CEO of Knight. “Knight's strategy across Canada and Latin America is to commercialize innovative pharmaceutical products. The launch of TULSA-PRO in Canada, a complex medical device technology, will be served best by Profound’s North American integrated commercial and clinical teams.\"\n \n\n “Currently, there is just one (but important) Canadian site offering the TULSA Procedure,” commented Profound’s CEO and Chairman, Arun Menawat. “Toronto’s renowned Sunnybrook Health Sciences Centre, the original innovator of the TULSA-PRO technology, has already performed more than 100 TULSA Procedures. Moving forward, as the results of the Level I prostate cancer CAPTAIN trial comparing the TULSA Procedure head-to-head with robotic radical prostatectomy are published in 2026 and beyond, we plan to use them to support our applications to the appropri...